$0.19
5.26%
Downside
Day's Volatility :5.26%
Upside
0.0%
15.84%
Downside
52 Weeks Volatility :97.84%
Upside
97.43%
Period | Aclarion Inc | Index (Russel 2000) |
---|---|---|
3 Months | -36.17% | 0.0% |
6 Months | -34.55% | 0.0% |
1 Year | -96.24% | 0.0% |
3 Years | -99.57% | -25.1% |
Market Capitalization | 1.8M |
Book Value | $0.20 |
Earnings Per Share (EPS) | -4.13 |
Wall Street Target Price | 1.25 |
Profit Margin | 0.0% |
Operating Margin TTM | -10350.57% |
Return On Assets TTM | -115.33% |
Return On Equity TTM | -714.18% |
Revenue TTM | 53.9K |
Revenue Per Share TTM | 0.02 |
Quarterly Revenue Growth YOY | -35.699999999999996% |
Gross Profit TTM | -4.9K |
EBITDA | -4.5M |
Diluted Eps TTM | -4.13 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.87 |
EPS Estimate Next Year | -0.54 |
EPS Estimate Current Quarter | -0.19 |
EPS Estimate Next Quarter | -0.13 |
What analysts predicted
Upside of 557.89%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 26.9K | - |
Net Income | -4.0M | - |
Net Profit Margin | -15.0K% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 48.7K | ↑ 80.88% |
Net Income | -4.8M | ↑ 19.04% |
Net Profit Margin | -9.8K% | ↑ 5114.91% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 60.3K | ↑ 23.93% |
Net Income | -3.5M | ↓ 26.21% |
Net Profit Margin | -5.9K% | ↑ 3983.75% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 60.4K | ↑ 0.25% |
Net Income | -9.1M | ↑ 157.79% |
Net Profit Margin | -15.1K% | ↓ 9212.27% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 75.4K | ↑ 24.75% |
Net Income | -4.9M | ↓ 46.1% |
Net Profit Margin | -6.5K% | ↑ 8561.32% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 25.5K | ↑ 13.1% |
Net Income | -1.2M | ↓ 11.04% |
Net Profit Margin | -4.6K% | ↑ 1260.51% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 25.5K | ↑ 0.0% |
Net Income | -1.2M | ↑ 0.3% |
Net Profit Margin | -4.7K% | ↓ 14.04% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 19.1K | ↓ 25.15% |
Net Income | -998.0K | ↓ 15.92% |
Net Profit Margin | -5.2K% | ↓ 574.25% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.8K | ↓ 27.63% |
Net Income | -1.3M | ↑ 26.79% |
Net Profit Margin | -9.2K% | ↓ 3936.39% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 10.1K | ↓ 26.69% |
Net Income | -2.4M | ↑ 89.6% |
Net Profit Margin | -23.7K% | ↓ 14549.44% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 11.0K | ↑ 8.47% |
Net Income | -1.2M | ↓ 48.39% |
Net Profit Margin | -11.3K% | ↑ 12435.61% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.4M | - |
Total Liabilities | 3.1M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.3M | ↓ 9.69% |
Total Liabilities | 8.4M | ↑ 167.38% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.9M | ↑ 46.27% |
Total Liabilities | 7.6M | ↓ 9.03% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 3.2M | ↑ 69.68% |
Total Liabilities | 1.4M | ↓ 81.39% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 2.5M | ↓ 23.27% |
Total Liabilities | 3.2M | ↑ 124.77% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.9M | ↓ 41.94% |
Total Liabilities | 736.4K | ↓ 48.07% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.0M | ↑ 7.68% |
Total Liabilities | 2.0M | ↑ 170.81% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.5M | ↓ 23.01% |
Total Liabilities | 2.4M | ↑ 18.9% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.5M | ↑ 59.39% |
Total Liabilities | 3.2M | ↑ 34.44% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 3.7M | ↑ 51.53% |
Total Liabilities | 1.2M | ↓ 61.67% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 3.1M | ↓ 17.13% |
Total Liabilities | 1.4M | ↑ 18.4% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.2M | - |
Investing Cash Flow | -267.2K | - |
Financing Cash Flow | 2.9M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -3.8M | ↓ 9.01% |
Investing Cash Flow | -179.0K | ↓ 33.0% |
Financing Cash Flow | 3.9M | ↑ 30.92% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -2.3M | ↓ 38.08% |
Investing Cash Flow | -152.0K | ↓ 15.09% |
Financing Cash Flow | 2.9M | ↓ 23.87% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -5.3M | ↑ 126.14% |
Investing Cash Flow | -207.9K | ↑ 36.75% |
Financing Cash Flow | 6.6M | ↑ 122.91% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -947.5K | ↓ 16.52% |
Investing Cash Flow | -60.9K | ↑ 26.25% |
Financing Cash Flow | 1.2M | ↓ 419.13% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -947.5K | ↑ 0.0% |
Investing Cash Flow | -60.9K | ↑ 0.0% |
Financing Cash Flow | 1.2M | ↑ 0.0% |
Sell
Neutral
Buy
Aclarion Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Aclarion Inc | 5.71% | -34.55% | -96.24% | -99.57% | -99.57% |
Solventum Corp | 7.14% | 11.24% | 4.86% | 4.86% | 4.86% |
Tempus Ai | -10.13% | 14.43% | 14.43% | 14.43% | 14.43% |
Veeva Systems Inc. | 2.53% | 5.63% | 12.04% | -32.67% | 46.51% |
Ge Healthcare Technologies Inc. | -4.49% | 11.72% | 25.56% | 43.74% | 43.74% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Aclarion Inc | NA | NA | NA | -0.87 | -7.14 | -1.15 | NA | 0.2 |
Solventum Corp | NA | NA | NA | 6.26 | 0.17 | 0.08 | NA | NA |
Tempus Ai | NA | NA | NA | -2.41 | 0.0 | 0.0 | NA | 0.64 |
Veeva Systems Inc. | 56.89 | 56.89 | 1.22 | 4.76 | 0.13 | 0.06 | NA | 32.04 |
Ge Healthcare Technologies Inc. | 23.93 | 23.93 | 2.29 | 4.28 | 0.22 | 0.06 | 0.0 | 18.2 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Aclarion Inc | Buy | $1.8M | -99.57% | NA | 0.0% |
Solventum Corp | Hold | $10.8B | 4.86% | NA | 15.73% |
Tempus Ai | NA | $7.9B | 14.43% | NA | -121.04% |
Veeva Systems Inc. | Buy | $34.5B | 46.51% | 56.89 | 23.91% |
Ge Healthcare Technologies Inc. | Buy | $39.9B | 43.74% | 23.93 | 8.56% |
Insights on Aclarion Inc
Revenue is up for the last 2 quarters, 10.11K → 10.97K (in $), with an average increase of 7.8% per quarter
Netprofit is up for the last 2 quarters, -2.39M → -1.23M (in $), with an average increase of 93.8% per quarter
In the last 1 year, Ge Healthcare Technologies Inc. has given 25.6% return, outperforming this stock by 121.8%
Geode Capital Management, LLC
UBS Group AG
TWO SIGMA SECURITIES, LLC
Citadel Advisors Llc
Ground Swell Capital, LLC
Tower Research Capital LLC
Organization | Aclarion Inc |
Employees | 4 |
CEO | Dr. Jeffrey John Thramann M.D. |
Industry | Miscellaneous |
Victoryshares International
$0.19
+0.54%
Clearbridge Focus Value Esg Etf
$0.19
+0.54%
Cabana Target Drawdwn 10 Etf
$0.19
+0.54%
Innovator Premium Income 40 Barrier Etf - April
$0.19
+0.54%
Relative Sentiment Tact Allo
$0.19
+0.54%
Teucrim Soybean Fund
$0.19
+0.54%
Biodesix Inc
$0.19
+0.54%
Euroseas Ltd
$0.19
+0.54%
Dawson Geophysical Co
$0.19
+0.54%